Last checked at (Sharecast News) - PureTech Health on Thursday said results from a study into a hair loss treatment developed by its affiliate Follica demonstrated a statistically significant 44% improvement in hair count.
The overall improvement of visible hair count after three months of treatment was 29% compared to baseline, which the FTSE 250-listed company said reflected a clinical benefit across the entire study population.
The company added that the historical benchmark for visible improvement among patients with male pattern baldness set by approved pharmaceuticals sits at 12%.
Follica's current treatment regimen sees patients experience targeted scalp disruption using a hair follicle neogenesis device, before then being administered with a topical on-market drug in order to create and grow new hair follicles.
PureTech's chief scientific officer Joseph Bolen said: "Currently, there are only two approved drugs on the market for the treatment of androgenetic alopecia, both of which have only demonstrated a 12% increase of non-vellus hair count over baseline.
"There remains a significant need for safe, effective, non-surgical treatments to grow new hair, and we believe the Follica data demonstrate strong promise as a potential new standard of care for the millions of people hoping to address their androgenetic alopecia."
PureTech Health shares were up by 2.48% at 276.70p at 0942 GMT.
23 Mar 2023 07:24
US Royalty Pharma strikes deal with PureTech Health on KarXT royalties
(Sharecast News) - US-listed Royalty Pharma has acquired an interest in PureTech Health's royalty in Karuna Therapeutics' KarXT drug for up to $500m, with $100m in cash up front and up to $400m in additional payments contingent on the achievement of certain regulatory and commercial milestones.
Read more